Janku, Filip
Beom, Seung-Hoon
Moon, Yong Wha
Kim, Tae Won
Shin, Young G.
Yim, Dong-Seok
Kim, Gun Min
Kim, Hyo Song
Kim, Sun Young
Cheong, Jae-Ho
Lee, Young Woo
Geiger, Barb
Yoo, Sanghee
Thurston, Archie
Welsch, Dean
Rudoltz, Marc S.
Rha, Sun Young
Article History
Received: 20 April 2022
Accepted: 23 June 2022
First Online: 8 July 2022
Declarations
:
: The study was conducted in accordance with Good Clinical Practice, the International Council for Harmonisation, and guidelines governing clinical study conduct and the ethical principles originating from the Declaration of Helsinki. The study was approved by each Institutional Review Board and patients provided written informed consent.
: All authors approved the final version of the manuscript.
: All patients provided written informed consent.
: The study was conducted in accordance with Good Clinical Practice, the International Council for Harmonisation, and guidelines governing clinical study conduct and the ethical principles originating from the Declaration of Helsinki. The study was approved by each Institutional Review Board.
: FJ reports research funding paid to the institution from Novartis, BioMed Valley Discoveries, Bioxcel Therapeutics, Bicara Therapeutics, Plexxikon, Deciphera, Piqur, Sanofi, SynthoRx, Merck, Spring Bank Pharmaceuticals, Symphogen, Synlogic, SQZ Biotechnologies, Ideaya Biosciences, Bayer, FujiFilm Corporation, Astex, Asana, Astellas, Agios, and Bristol-Myers Squibb; is or has been on scientific advisory board or provided paid consulting services for Deciphera, IFM Therapeutics, Synlogic, Guardant Health, Ideaya, PureTech Health, Jazz Pharmaceuticals, Cardiff Oncology, Immunomet, Primmune Therapeutics, Sotio, Bicara Therapeutics, Petra Therapeutics; and has ownership interest in Cardiff Oncology. MSR reports stock and ownership interests in Novartis, Kura Oncology, Kronos Bio, Mycovia Pharmaceuticals, ENB Therapeutics, ImmunoMet Therapeutics, FemSelect, Broadspot, Cerus, and Healionics, is or has been in a consulting or advisory role for Blueprint Medicines, Immunomet Therapeutics, Nextcure Inc, Novellus Ltd, Epivax Therapeutics, Premier Research, and Ikena Oncology.
: FJ reports research funding paid to the institution from Novartis, BioMed Valley Discoveries, Bioxcel Therapeutics, Bicara Therapeutics, Plexxikon, Deciphera, Piqur, Sanofi, SynthoRx, Merck, Spring Bank Pharmaceuticals, Symphogen, Synlogic, SQZ Biotechnologies, Ideaya Biosciences, Bayer, FujiFilm Corporation, Astex, Asana, Astellas, Agios, and Bristol-Myers Squibb; is or has been on scientific advisory board or provided paid consulting services for Deciphera, IFM Therapeutics, Synlogic, Guardant Health, Ideaya, PureTech Health, Jazz Pharmaceuticals, Cardiff Oncology, Immunomet, Primmune Therapeutics, Sotio, Bicara Therapeutics, Petra Therapeutics; and has ownership interest in Cardiff Oncology. MSR reports stock and ownership interests in Novartis, Kura Oncology, Kronos Bio, Mycovia Pharmaceuticals, ENB Therapeutics, ImmunoMet Therapeutics, FemSelect, Broadspot, Cerus, and Healionics, is or has been in a consulting or advisory role for Blueprint Medicines, Immunomet Therapeutics, Nextcure Inc, Novellus Ltd, Epivax Therapeutics, Premier Research, and Ikena Oncology.